Key statistics
As of last trade, Exagen Inc (E08A:FRA) traded at 2.88, 12.50% above the 52 week low of 2.56 set on Mar 11, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 2.88 |
|---|---|
| High | 2.88 |
| Low | 2.88 |
| Bid | 2.70 |
| Offer | 2.80 |
| Previous close | 3.08 |
| Average volume | 15.33 |
|---|---|
| Shares outstanding | 22.66m |
| Free float | 14.62m |
| P/E (TTM) | -- |
| Market cap | 79.32m USD |
| EPS (TTM) | -0.9257 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 07:16 GMT.
More ▼
Announcements
- Exagen Inc. Announces Select Preliminary 2025 Financial Results
- Exagen Inc. to Participate in Fourth Quarter Investor Conferences
- Exagen Inc. Reports Strong Q3 2025 Results
- Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
- Exagen Inc. to Participate in Third Quarter Investor Conferences
- Exagen Inc. Reports Strong Q2 2025 Results
- Exagen Inc. Appoints Chas McKhann to Board of Directors
- Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
- Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
- Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
More ▼
